Clearmind Medicine Announces 1-for-8 Reverse Share Split

Clearmind Medicine Inc. has announced a 1-for-8 reverse share split of its common shares. Under the terms of the split, every eight existing common shares will be consolidated into one common share. This action will reduce the company\'s issued and outstanding common shares from 4,059,227 to approximately 507,404 shares. No fractional shares will be issued; instead, all fractional shares will be rounded up to the nearest whole share. The reverse split also necessitates proportionate adjustments to the exercise price and the number of shares issuable under outstanding options and warrants. The company’s common shares are expected to begin trading on the Nasdaq Capital Market on a split-adjusted basis starting Monday, October 5, 2026. This corporate action does not change the company\'s authorized share capital. The new CUSIP number for the common shares following the split will be 185053709. This filing is incorporated by reference into several of the registrant\'s existing Registration Statements.